levetiracetam
levetiracetam: developed by 1 company · 4 clinical trials tracked · 1 FDA decision.
levetiracetam evidence translation
What we can confirm
1 FDA record · 4 tracked trials
What it means
What to watch
Prepared research question
How could levetiracetam → NEXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 2 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) | Approved |
| NEXUS BIOPHARMA INC (NEXS) | Approved |
Clinical Trials (4)
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
Primary endpoint: Termination of SE
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Primary endpoint: Safety and adverse events (AEs)
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Primary endpoint: M/P ratio
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
Primary endpoint: Neurocognitive Function
Frequently asked questions
Who is developing levetiracetam?
levetiracetam is being developed by NEXUS BIOPHARMA INC.
How many clinical trials involve levetiracetam?
BioSniper tracks 4 clinical trials involving levetiracetam.
What is levetiracetam's latest FDA decision?
The most recent tracked FDA decision for levetiracetam is Approval, dated July 6, 2020.